Nueva terapia para el cáncer de páncreas

New therapy to treat pancreatic cancer

Researchers from the Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBm), a joint center of the CSIC and the UAM, have published a study in the prestigious journal GUT in which they unravel the important components of the fibroinflammatory microenvironment of pancreatic cancer, the fourth leading cause of cancer-related death worldwide.

This study details the identification of lysyl oxidase-like protein 2 (LOXL2) as a key factor in the metastasis of this high-mortatility tumor. This may represent a new therapeutic approach to reduce the metastatic potential of pancreatic ductal adenocarcinoma tumor cells

This work, published in the prestigous journal GUT, has been led by Drs. Bruno Sainz Anding and Amparo Cano and carried out by the Cancer Stem Cells and Fibroinflammatory Microenvironment Group of the Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBm) CSIC-UAM and the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). This study has been supported by the Fero Foundation, the ISCIII, the Spanish Association Against Cancer (AECC) and the group coordinated by Dr. Alfredo Carrato within the gastrointestinal tumor program of CIBERONC, in addition to an essential collaboration with the CIBERONC breast cancer program group led by Dra. Gema Moreno-Bueno, from the UAM and the MD Anderson International Foundation.

The researchers have tried to better understand the role of the tumor microenvironment in promoting metastasis in pancreatic cancer. A hallmark of this tumor type is its collagen-rich extracellular matrix and fibrotic stroma. Several proteins secreted from tumor cells into this microenvironment play an essential role in the creation of its organized stroma. These proteins include those of the lysyl oxidase family of proteins, in particular LOXL2, which is responsible for collagen and elastin binding to the extracellular matrix and, as observed in other tumor types, is involved in eliciting certain biochemical, physical and mechanical effects capable of modulating tumor progression. In the current study, led by Marta Alonso-Nocelo and Laura Ruiz-Cañas (co-first authors), several genetically modified mouse models of pancreatic cancer were used to demonstrate in vivo, for the first time, that the loss of Loxl2 significantly reduces tumor metastasis and prolongs overall survival, whereas the opposite was observed when Loxl2 was overexpressed in mice. Furthermore, the group has demonstrated that tumor-associated macrophages are actively involved in this process and are able to promote Loxl2 expression through the secreted protein oncostatin M (OSM). Importantly, this study shows in a pioneering way that Loxl2 expression plays an important role in PDAC metastasis, and that compounds blocking Loxl2 in combination with inhibitors of TAMs or OSM-mediated signaling may represent a new therapeutic approach to reduce the metastatic potential of PDAC tumor cells.

"Understanding the fibroinflammatory microenvironment of pancreatic cancer is essential for designing new therapies for patients suffering from this devastating cancer" says Dr. Bruno Sainz Anding, and Drs. Moreno-Bueno and Cano agree, stressing that "the correct molecular characterization of pancreatic cancer will allow, in the future, to correctly classify patients and advance in the design of personalized therapies".

The project was supported by the Fero Foundation and projects from the Spanish Association Against Cancer (AECC).

Figure. Role of LOXL2 in PDAC. Tumor-infiltrating macrophages are converted to tumor-associated macrophages (TAMs) via "TAM-promoting factors" secreted by PDAC tumor cells. TAMs, in turn, secrete Oncostatin M (OSM) that binds to the OSM receptor (OSMR) activating downstream programs, including the transcription of LOXL2. LOXL2 is secreted by the tumor cells into the microenvironment facilitating collagen fiber crosslinking, resulting in an organized extracellular matrix (ECM) with increased stiffness, epithelial tension and mechanocontractility. This organized ECM facilitates communication (e.g., via exosomes) with secondary organs, promoting the formation of premetastatic niches replete with bone marrow (BM)-derived macrophages, facilitating the eventual intravasation of tumor cells and subsequent metastases. Inhibitors targeting LOXL2, TAMs and/or OSM signaling may represent a new therapeutic approach to reduce the metastatic potential of PDAC tumor cells.